Life Science Compliance Update

January 19, 2016

Webinar: Managing the Risk of Open Payments – Validate Spend Report Before CMS Submission

With the next filing period for spend data under the Sunshine Act coming up quickly, Ned Mumtaz and Brian Dahl are hosting a webinar on how to help you manage the risk of open payments and open payments reporting. The webinar will take place on Thursday, January 21, 2016, at 2:00 pm EST. The webinar will explain how you can work to protect yourself from risks of audits or fines, even before you submit your final report to the Centers for Medicare and Medicaid Services (CMS).

Mumtaz and Dahl will discuss a range of important topics, including some of the potential implications of public availability of this data and how governmental authorities may use the Sunshine Act data to generate enforcement actions.

If you attend the webinar, you will learn how to run an independent audit on your spend before building state and federal reports, spot an outlier before submitting your final report, and improve your compliance program using data analytics.

Brian Dahl is the principal of Dahl Compliance Consulting, LLC, and is the architect of the Corporate Compliance Programs at both Teva Pharmaceuticals and Takeda Pharmaceuticals. Ned Mumtaz is leading Streebo's transparency directive program in the United States and European Union; he has over twenty years of experience in the pharmaceutical industry and has led several Sunshine implementation programs in the United States.

The webinar is moderated by Thomas Sullivan, the Chief Editor of Policy and Medicine. Policy and Medicine has been the number one information source for the Physician Payment Sunshine Act for the past five years, according to Google.

If you are interesting in attending, you can register here.

January 13, 2016

CBI’s Pharmaceutical Compliance Congress 2016

This year, CBI is hosting the Thirteenth Annual Pharmaceutical Compliance Congress (PCC) January 26 – 27, 2016, at the Ritz Carlton in Washington, D.C.

This two-day event is packed with programming, including discussion of issues such as mergers and acquisitions, global transparency, off-label promotion, risk monitoring, cross-border compliance, and enforcement priorities.

Day One of the event starts with an opening address from Ashley Watson, Chief Ethics and Compliance officer at Merck & Co, Inc., who will be speaking about how to unite compliance and the business, to raise the bar and reinforce global collaboration. Following that is a showcase, where attendees will hear from leading Chief Compliance Officers on a variety of the most pressing issues impacting today's business world. CCOs who will be on that showcase panel include: Trudy Tan, AstraZeneca; Jill Fallows-Macaluso, Novo Nordisk Inc.; and John Crisan, Johnson & Johnson. Later that morning, attendees will also hear from a selection of USAO on healthcare fraud enforcement trends and future compliance issues, and former prosecutors of high-profile healthcare fraud cases.

A Chief Compliance Officer Summit will take place the afternoon of January 26, where Chief Compliance Officers will be permitted to discuss common questions, challenges, and issues that are facing CCOs today. For those attendees who are not CCOs, many opportunities await them, including a choice of six varied workshops, covering a wide variety of material, including government pricing updates, pre-M&A due diligence, and the unique risks associated with specialty drugs. Following the workshops, attendees will have their choice of four different tracks of speakers, including tracks focused on product promotional compliance and compliance considerations for clinical research and R&D. At the close of day one, a wine and cheese reception is held for networking purposes.

Day Two opens with an update from the FBI, presented by Jeffrey S. Salley, Special Agent in Charge, followed by an address by Robin Usi, Director of the Division of Data and Informatics at CMS. Day Two continues with an option of five different tracks, ranging in topics from global and international compliance strategies to off-label risks and controls. Day Two ends with four working group discussion options, including one discussion on the 21st Century Cures Act and its impact on compliance, where attendees will engage in small group conversation with peers, sharing first hand experience and asking constructive questions to spark dialogue.

The PCC sees over 400 attendees annually in a variety of backgrounds, with 74% of attendees being from the bio/pharma/device community.

Additionally, this year, CBI is hosting a "PCC Prelude" the afternoon of January 25, 2016. There are two events that make up the PCC Prelude, both from 3:00pm – 5:00pm and invitation-only, the Emerging Leaders' Summit and the Advanced Think Tank Summit for Small Mid-Sized Life Sciences Companies.

If you are interested in attending the Thirteenth Annual Pharmaceutical Compliance Congress, you can register here. As an added bonus, Policy & Medicine readers are offered a $400* registration discount by entering the code PCCPM4 with their registration.

* This discount applies to standard rate and may not be combined with other offers or applied to an existing registration.

October 29, 2015

The Fourth Annual Corporate Compliance & Transparency in the Pharmaceutical Industry Europe

The Fourth Annual Corporate Compliance & Transparency in the Pharmaceutical Industry, presented by Fleming Europe, will take place February 24 – 25, 2016 in Zurich, Switzerland.

The two-day event is packed with speakers who will aim to provide attendees with: an update on the implementation of the Disclosure Code and the first outcomes and how to evaluate your implementation process; tips on how to unravel compliance challenges relating to data privacy; an understanding of how to optimize interactions with health care providers and health care organizations through a fully compliant and transparent strategy to obtain consent; and information on compliance implications and concerns for merging corporate cultures.

On Wednesday, February 24, 2016, the day will begin with an update on implementation of the disclosure code from the European Federation of Pharmaceutical Industries and Associations. Richard Bergstrom of the EFPIA will discuss do's and don't when implementing EFPIA's codes, what will happen once the data is disclosed, and challenges relating to external communication and specific countries relating to disclosure. The morning continues with three separate discussions about transparency: a panel on transparency obligations; a panel on local perspectives – disclosure and transparency lessons learned; and keynote on data privacy and transparency requirements under the EU Data Protection Directive. Following lunch, the afternoon brings more panels and discussions, including a talk on how to determine fair market value, a keynote from Adrien Van Den Hoven of European Generic and Biosimilars Medicine Association, and a case study on communication and relationships with health care providers. Wednesday ends with a networking cocktail reception.

Thursday, February 25, 2016, begins with a panel on best practices: compliance program structure and effectiveness, with speakers from Sandoz, Acino Pharma AG, and Biogen. Following the panel, Nina Stoeckel from Merck KGaA will speak about how critical team structure is to success. Marit Pless will conclude the morning session by providing a roadmap for conducting internal investigations. The afternoon will be spent hearing from representatives from AstraZeneca and Johnson & Johnson on topics such as compliance and risk assessment and how to organize an approach for communicating, training, and monitoring third parties.

If you're interested in attending the Fourth Annual Corporate Compliance & Transparency in the Pharmaceutical Industry, you can register here.


Preview | Powered by FeedBlitz


February 2016
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29